During the past decade, Washington University School of Medicine; Department of Neurology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Washington University School of Medicine; Department of Neurology" #1 sponsor was "Acorda Therapeutics" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Forbes Norris MDA/ALS Research Center" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "University of Texas Southwestern Medical Center" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Washington University School of Medicine; Department of Neurology" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Muscular Dystrophy Association" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Washington University School of Medicine; Department of Neurology" are "Multiple Sclerosis" (2 trials), "Amyotrophic Lateral Sclerosis" (1 trials), "Generalized Myasthenia Gravis" (1 trials), "Inclusion Body Myositis" (1 trials) and "Multiple Sclerosis (MS)" (1 trials). Many other conditions were trialed in "Washington University School of Medicine; Department of Neurology" in a lesser frequency.

Most popular intervention types in "Washington University School of Medicine; Department of Neurology" are "Drug" (8 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Ocrelizumab" (2 trials), "Etanercept" (1 trials), "Fampridine-SR" (1 trials) and "Fampridine-SR b.i.d. (Twice Daily)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Washington University School of Medicine; Department of Neurology" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Washington University School of Medicine; Department of Neurology". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Washington University School of Medicine; Department of Neurology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Washington University School of Medicine; Department of Neurology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".